These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1113 related articles for article (PubMed ID: 27663389)

  • 1. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.
    Hardcastle J; Mills L; Malo CS; Jin F; Kurokawa C; Geekiyanage H; Schroeder M; Sarkaria J; Johnson AJ; Galanis E
    Neuro Oncol; 2017 Apr; 19(4):493-502. PubMed ID: 27663389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy.
    Panagioti E; Kurokawa C; Viker K; Ammayappan A; Anderson SK; Sotiriou S; Chatzopoulos K; Ayasoufi K; Johnson AJ; Iankov ID; Galanis E
    J Clin Invest; 2021 Jul; 131(13):. PubMed ID: 34196308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme.
    Liu C; Sarkaria JN; Petell CA; Paraskevakou G; Zollman PJ; Schroeder M; Carlson B; Decker PA; Wu W; James CD; Russell SJ; Galanis E
    Clin Cancer Res; 2007 Dec; 13(23):7155-65. PubMed ID: 18056196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma.
    Kiyokawa J; Kawamura Y; Ghouse SM; Acar S; Barçın E; Martínez-Quintanilla J; Martuza RL; Alemany R; Rabkin SD; Shah K; Wakimoto H
    Clin Cancer Res; 2021 Feb; 27(3):889-902. PubMed ID: 33257429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.
    Zeng J; See AP; Phallen J; Jackson CM; Belcaid Z; Ruzevick J; Durham N; Meyer C; Harris TJ; Albesiano E; Pradilla G; Ford E; Wong J; Hammers HJ; Mathios D; Tyler B; Brem H; Tran PT; Pardoll D; Drake CG; Lim M
    Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):343-9. PubMed ID: 23462419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade.
    Saha D; Martuza RL; Rabkin SD
    Cancer Cell; 2017 Aug; 32(2):253-267.e5. PubMed ID: 28810147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma.
    Saha D; Martuza RL; Rabkin SD
    Immunotherapy; 2018 Jul; 10(9):779-786. PubMed ID: 30008259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemagglutinating virus of Japan-envelope containing programmed cell death-ligand 1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma.
    Sugii N; Matsuda M; Okumura G; Shibuya A; Ishikawa E; Kaneda Y; Matsumura A
    Cancer Sci; 2021 Jan; 112(1):81-90. PubMed ID: 33155337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of protein phosphatase-2A with LB-100 enhances antitumor immunity against glioblastoma.
    Maggio D; Ho WS; Breese R; Walbridge S; Wang H; Cui J; Heiss JD; Gilbert MR; Kovach JS; Lu RO; Zhuang Z
    J Neurooncol; 2020 Jun; 148(2):231-244. PubMed ID: 32342332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma.
    Speranza MC; Passaro C; Ricklefs F; Kasai K; Klein SR; Nakashima H; Kaufmann JK; Ahmed AK; Nowicki MO; Obi P; Bronisz A; Aguilar-Cordova E; Aguilar LK; Guzik BW; Breakefield X; Weissleder R; Freeman GJ; Reardon DA; Wen PY; Chiocca EA; Lawler SE
    Neuro Oncol; 2018 Jan; 20(2):225-235. PubMed ID: 29016938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers.
    Woroniecka KI; Rhodin KE; Dechant C; Cui X; Chongsathidkiet P; Wilkinson D; Waibl-Polania J; Sanchez-Perez L; Fecci PE
    Clin Cancer Res; 2020 Mar; 26(6):1349-1358. PubMed ID: 31871298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
    Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
    J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth.
    Lamano JB; Lamano JB; Li YD; DiDomenico JD; Choy W; Veliceasa D; Oyon DE; Fakurnejad S; Ampie L; Kesavabhotla K; Kaur R; Kaur G; Biyashev D; Unruh DJ; Horbinski CM; James CD; Parsa AT; Bloch O
    Clin Cancer Res; 2019 Jun; 25(12):3643-3657. PubMed ID: 30824583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.
    Antonios JP; Soto H; Everson RG; Moughon D; Orpilla JR; Shin NP; Sedighim S; Treger J; Odesa S; Tucker A; Yong WH; Li G; Cloughesy TF; Liau LM; Prins RM
    Neuro Oncol; 2017 Jun; 19(6):796-807. PubMed ID: 28115578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia.
    Shen W; Patnaik MM; Ruiz A; Russell SJ; Peng KW
    Blood; 2016 Mar; 127(11):1449-58. PubMed ID: 26712908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy.
    Passaro C; Alayo Q; De Laura I; McNulty J; Grauwet K; Ito H; Bhaskaran V; Mineo M; Lawler SE; Shah K; Speranza MC; Goins W; McLaughlin E; Fernandez S; Reardon DA; Freeman GJ; Chiocca EA; Nakashima H
    Clin Cancer Res; 2019 Jan; 25(1):290-299. PubMed ID: 30279232
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Shevtsov M; Pitkin E; Ischenko A; Stangl S; Khachatryan W; Galibin O; Edmond S; Lobinger D; Multhoff G
    Front Immunol; 2019; 10():454. PubMed ID: 30967859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade.
    Nair S; Mazzoccoli L; Jash A; Govero J; Bais SS; Hu T; Fontes-Garfias CR; Shan C; Okada H; Shresta S; Rich JN; Shi PY; Diamond MS; Chheda MG
    JCI Insight; 2021 Jan; 6(1):. PubMed ID: 33232299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic measles virus strains have significant antitumor activity against glioma stem cells.
    Allen C; Opyrchal M; Aderca I; Schroeder MA; Sarkaria JN; Domingo E; Federspiel MJ; Galanis E
    Gene Ther; 2013 Apr; 20(4):444-9. PubMed ID: 22914495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme.
    Phuong LK; Allen C; Peng KW; Giannini C; Greiner S; TenEyck CJ; Mishra PK; Macura SI; Russell SJ; Galanis EC
    Cancer Res; 2003 May; 63(10):2462-9. PubMed ID: 12750267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.